Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00550537
- Locations
- 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Family Quality of Life Among Families With a Member Who is a Cancer Patient
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 366
- Registration Number
- NCT00544336
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00544648
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Purchase Cancer Group - Paducah, Paducah, Kentucky, United States
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00520845
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00514020
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT00512798
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT00503997
- Locations
- 🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States
🇺🇸Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸MBCCOP - Meharry Medical College - Nashville, Nashville, Tennessee, United States
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
- Conditions
- Interventions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT00503776
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2013-04-02
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT00499668
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00499681
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States